Vol.24/No.11 | Oncology Live®

Examining the Role of BTK Inhibitors in Mantle Cell Lymphoma

June 27, 2023

As part of the diagnostic work-up for a patient with newly diagnosed MCL, it is important to establish prognostic disease biology factors such as classical nodal morphology vs blastoid variant vs leukemic variant, TP53 mutation status, and Ki-67 reflective of proliferation.

Leveraging BTK Inhibitors in Chronic Lymphocytic Leukemia

June 26, 2023

The choice of BTK inhibitor regimen for patients with chronic lymphocytic leukemia must be tailored to the patient, taking into consideration their preferences and comorbidities, as well as potential treatment-related adverse effects.

Operational Innovations, AI to Play Vital Roles in EOM Data Collection

June 23, 2023

Oncology Live®

The arrival of the Enhancing Oncology Model has renewed the uncertainties surrounding value-based care approaches for practices opting into the next wave of Center for Medicare & Medicaid Services performance structure

Optimizing Treatment Patterns in Relapsed or Refractory Differentiated Thyroid Cancer

June 21, 2023

A panel of head and neck cancer experts discussed the nuances of managing relapsed or refractory DTC with lenvatinib or sorafenib, as well as sequencing considerations with targeted therapies in the second-line setting and beyond for patients with relapsed or refractory disease.

Strides in GI Cancer Subsets Influence Advances

June 20, 2023

Tanios S. Bekaii-Saab, MD, highlights the unmet needs in GI malignancies and discusses how interdisciplinary meetings, such as the 20th Annual Meeting of the International Society of Gastrointestinal Oncology, provide the framework for disseminating information and driving innovative advances.